Lifesaving medications for two common heart conditions listed on the PBS

Australians suffering two different heart conditions will be able to access two new medications on the Pharmaceutical Benefits Scheme (PBS), saving patients up to $122,000 per year in treatment costs.

From May 1, mavacamten, also known as Camzyos, and tafamidis, which is sold under the brand name Vyndamax, will cost eligible patients a maximum of $31.60 per script or $7.70 for concession card holders.

Vyndamax, which previously cost about $122,000 for every year of treatment, is used to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM).

The disease leads to the build-up of an abnormal protein in the heart that can lead to heart failure if left untreated.

Camzyos, which costs about $33,000 for every year of treatment, will also be listed on the PBS for the first time.

The medication is also used to treat HCM.

A combined 4800 Australians are expected to benefit from the changes.

Health Minister Mark Butler said affordable and ready access to the drugs would ensure the quick treatment of cardiomyopathy.

“By listing Vyndamax and Camzyos on the PBS, we’re giving patients and their doctors new options for treatment at an affordable price,” he said.

“It’s part of the Albanese government’s commitment to keep medicines cheaper for Australians.”

In November last year, the federal government also listed breast cancer drug Verzenio on the PBS,

Leave a Comment